You searched for "Prostate cancer"
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...
Incidence and risk factors of suicide after a prostate cancer diagnosis
This is an observational study looking at 1,281,393 men diagnosed with prostate cancer and 842,294 matched prostate cancer-free men. There was an overall increased relative risk of suicide of 2.01 in men diagnosed with prostate cancer compared to those without,...
Ulcerative colitis has a positive association with prostate cancer risk
This large-scale meta-analysis, incorporating studies from several population-based studies, evaluated the association between inflammatory bowel disease (IBC) and prostate cancer (Pca). Emerging evidence has suggested that IBD is a risk factor for extra-intestinal malignancies which may be due to an...
Factors and time to conversion from prostate cancer active surveillance to treatment
Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...
Intermittent vs. continuous hormonal therapy for metastatic prostate cancer
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...
An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences
This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....
The potential of statin use in castrate resistant prostate cancer treatment
One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...Black men are more at risk from prostate cancer, but we won’t let it stay that way – an update from Prostate Cancer Research
- CHARITY FOCUS - Focusing on all of disease characteristics, societal factors, and better communication gives us real potential to fix a disparity that has persisted for too long. When it comes to health inequity, the numbers are stark. Black...
Is TRUS and biopsy obsolete as a diagnostic test for prostate cancer: refining the perineal biopsy technique?
Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study
This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...
